Human Subjects

ABSTRACT Stroke survivors are at high risk for cardiovascular mortality which can be in part mitigated by increasing physical activity. Self-efficacy for exercise is known to play a role in adoption of exercise...

MAUI, Hawaii -- At Retina Meeting 2012 today, Reid Schindler, M.D., presented positive Phase I data from a human study designed to assess a new investigational therapy to treat Wet Age-related Macular Degeneration...

Study also Demonstrated 100% Sustained Virologic Response 12-Weeks Post Treatment with Quadruple Therapy Phase II Investigational Data Published Today in the New England Journal of Medicine PRINCETON, N.J. -- Bristol-Myers Squibb Company (NYSE:...

CARY, N.C. -- The CEO Roundtable on Cancer recently accredited Hudson Valley Federal Credit Union (HVFCU) with the CEO Cancer Gold Standard([TM]) recognizing the credit union's efforts to reduce the risk of cancer...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/8f5a37/dermatology_therap) has announced the addition of the "Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and...

MIAMI -- Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians...

Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells MARLBOROUGH, Mass. -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of...

Leading European CRO Chooses 'Flexible and Affordable' Clinical Trial Management (CTMS) Technology NEWTOWN, Pa. -- BioClinica([R]), Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, announced today a new agreement with...

ROCHESTER, Minn. -- An investigational drug called regorafenib slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer, an international phase III clinical trial found. The findings were...

NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects. The study is being conducted...

ROCKVILLE, Md. -- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012. "Rexahn...

LUTZ, Fla. -- CytoDyn Inc. (the "Company")(OTC QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency virus and other antibody applications, announced today that it...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/b3725d/endpointsclinical) has announced the addition of the "Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma" report to their offering. GBI Research,...

BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced updates to the U.S. Prescribing Information (PI) for ADCETRIS[TM] (brentuximab vedotin). The revised PI will include the following updated information: * A boxed...

STEVENSON, Md. -- The law firm of Brower Piven, A Professional Corporation, is investigating potential securities fraud claims against GenVec, Inc. ("GenVec") (NASDAQ: GNVC) regarding whether GenVec may have issued materially false or...

TAMPA, Fla. & MINNEAPOLIS -- Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that an article published by 'MyHealthNewsDaily' was featured on the Fox News...

WASHINGTON -- The U.S. Department of Health and Human Services will invest approximately $1.8 million to increase its efforts to improve the treatment and prevention of HIV and other sexually transmitted diseases (STD)...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/5fb90b/endpoints_clinic) has announced the addition of the "Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials"...

The company has also reported exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684. Based upon these results, the company is planning further exploration of...